Mawson Lakes Office, IW 2-1908 83023569
Professor of Pharmaceutical Science
Clive Prestidge is currently a Professor within Clinical and Health Science, a lead researcher within UniSA's Cancer Research Institute and head of the Nanostructure and Drug Delivery research group.
Clive is the author of over 250 refereed international journal articles, textbook chapters and conference papers and over 100 major project reports to industry. He has supervised more than 35 PhD, 10 MSc and 30 Honours students and has taken a leadership role in a number of major collaborative projects in association with national and international industries, the ARC, and University researchers from Australia and overseas. Prof Prestidge has attracted competitive research grants worth more than... Read more
About me
Professor of Pharmaceutical Science
Clive Prestidge is currently a Professor within Clinical and Health Science, a lead researcher within UniSA's Cancer Research Institute and head of the Nanostructure and Drug Delivery research group.
Clive is the author of over 250 refereed international journal articles, textbook chapters and conference papers and over 100 major project reports to industry. He has supervised more than 35 PhD, 10 MSc and 30 Honours students and has taken a leadership role in a number of major collaborative projects in association with national and international industries, the ARC, and University researchers from Australia and overseas. Prof Prestidge has attracted competitive research grants worth more than $15M from government and industry sources.
Clive was the founder of Ceridia Pty Ltd, a clinical stage biopharmaceutical company established to commercial the the Lipoceramic drug delivery technology he invented.
The Prestidge research group is focused on Drug delivery, Nanomedicine and BioPharmaceutical Engineering. Its Primary Mission is to: (1) Engineer novel particle based biomaterials with specific biological activity and their application to solve biopharmaceutical challenges. (2) Determine mechanisms for bioactivity through advanced biophysical analysis (3) Develop drug delivery solutions to address unmet clinical needs. Some of our Grand Challenges are to: (1) Deliver Challenging Therapeutic Molecules – For Better Medicines (2) Eradicate Bacterial Biofilms (3) Optimise Biotech and Pharmaceutical Processing and Manufacture
About me
About me
Doctor of Philosophy University of Bristol
Bachelor of Science University of Loughborough
The Prestidge research group is focused on Nanomedicine and BioPharmaceutical Engineering. Its Primary Mission is to: (1) Engineer novel particle based biomaterials with specific biological activity and their application to solve biopharmaceutical challenges. (2) Determine mechanisms for bioactivity through advanced biophysical analysis (3) Develop drug delivery solutions to address unmet clinical needs. Some of our Grand Challenges are to: (1) Deliver Challenging Therapeutic Molecules – For Better Medicines (2) Eradicate Bacterial Biofilms (3) Optimise Biotech and Pharmaceutical Processing and Manufacture
Research
Excludes commercial-in-confidence projects.
Omega-3 Fatty Acid Quantification in Patient Plasma Samples, Pharmako Biotechnologies Pty Ltd, 15/10/2024 - 31/03/2025
Maximising the antimicrobial and anti-inflammatory performance of next generation therapeutics for Chronic Rhinosinusitis, NHMRC - Project Grant, 01/01/2019 - 31/12/2021
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC - Centre of Excellence, 01/04/2014 - 29/06/2021
Optimization and validation of assay of French protocol for phenotyping patient samples for treatment optimization, Pari-Passou Medical Consultancy, 03/08/2020 - 31/12/2020
Mechanistic insight into Pharmako's Oral Curcumin Product: LipiSperse®, Pharmako Biotechnologies Pty Ltd, 03/10/2018 - 25/12/2019
Targeting particulate carriers to epithelial M cells, ARC - Linkage Project, 15/12/2015 - 30/09/2019
Targeting Particulate Carriers to Epithelial M Cells, CeramiSphere Pty Ltd, 01/01/2016 - 30/06/2019
Lipoceramic reformulation of simvastatin, Reformpharm Pty Ltd, 23/11/2016 - 31/12/2017
Research Infrastructure Fund (RIF) Grant 2016 Round 2 - Biofilm Testing Facility, Adelaide Integrated Bioscience Laboratories, 28/11/2016 - 31/12/2017
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2016 |
46
36
4
|
| 2015 |
Open access
239
210
252
|
| 2015 |
31
29
|
| Year | Output |
|---|---|
| 2020 |
4
1
|
| 2016 |
|
| 2014 |
6
|
| 2014 |
1
|
| 2012 |
1
1
|
| 2008 |
|
| Year | Output |
|---|---|
| 2025 |
Open access
|
| 2025 |
Open access
|
| 2025 |
Open access
|
| 2025 |
Open access
1
1
5
|
| 2025 |
|
| 2025 |
Open access
1
1
|
| 2024 |
Open access
13
10
3
|
| 2024 |
Open access
9
9
29
|
| 2024 |
Open access
3
71
|
| 2024 |
Open access
2
|
| 2024 |
Open access
87
|
| 2024 |
Open access
8
6
3
|
| 2024 |
Open access
1
|
| 2024 |
1
|
| 2024 |
Open access
2
3
15
|
| 2024 |
Open access
26
130
|
| 2024 |
Open access
3
|
| 2024 |
Open access
7
6
85
|
| 2024 |
Open access
|
| 2024 |
Open access
4
4
|
| 2024 |
Open access
3
3
1
|
| 2024 |
Open access
|
| 2024 |
3
4
1
|
| 2024 |
Open access
2
2
4
|
| 2024 |
|
| 2023 |
Open access
2
2
|
| 2023 |
Open access
5
4
64
|
| 2023 |
1
|
| 2023 |
Open access
7
8
|
| 2023 |
Open access
3
3
2
|
| 2023 |
Open access
16
15
11
|
| 2023 |
Open access
12
9
|
| 2023 |
Open access
41
|
| 2023 |
6
5
|
| 2023 |
Open access
18
18
5
|
| 2023 |
Open access
10
10
21
|
| 2023 |
Open access
25
22
4
|
| 2023 |
Open access
19
19
8
|
| 2023 |
Open access
9
6
4
|
| 2023 |
Open access
8
7
|
| 2023 |
13
15
|
| 2023 |
7
8
5
|
| 2022 |
4
4
3
|
| 2022 |
12
12
66
|
| 2022 |
Open access
10
10
121
|
| 2022 |
47
43
70
|
| 2022 |
Open access
5
2
6
|
| 2022 |
Open access
262
|
| 2022 |
Open access
32
26
5
|
| 2022 |
Open access
8
7
|
| 2022 |
32
28
54
|
| 2022 |
Open access
7
9
3
|
| 2022 |
Open access
5
4
7
|
| 2022 |
Open access
4
3
1
|
| 2022 |
8
6
1
|
| 2022 |
14
14
2
|
| 2022 |
Open access
9
7
333
|
| 2022 |
Open access
9
8
1
|
| 2021 |
11
10
50
|
| 2021 |
Open access
19
17
1
|
| 2021 |
16
18
15
|
| 2021 |
Open access
22
21
|
| 2021 |
Open access
12
9
|
| 2021 |
Open access
27
25
4
|
| 2021 |
Open access
9
9
4
|
| 2021 |
Open access
5
4
5
|
| 2021 |
66
65
11
|
| 2021 |
Open access
54
48
3
|
| 2021 |
54
52
94
|
| 2021 |
47
42
9
|
| 2021 |
28
25
63
|
| 2021 |
Open access
44
36
4
|
| 2021 |
Open access
9
9
10
|
| 2020 |
29
26
32
|
| 2020 |
Open access
9
9
2
|
| 2020 |
Open access
9
9
1
|
| 2020 |
Open access
23
21
20
|
| 2020 |
Open access
5
5
|
| 2020 |
Open access
27
26
2
|
| 2020 |
Open access
16
17
2
|
| 2020 |
11
11
3
|
| 2020 |
23
19
4
|
| 2020 |
7
6
1
|
| 2020 |
Open access
31
29
|
| 2020 |
15
13
|
| 2020 |
47
45
2
|
| 2020 |
Open access
7
7
|
| 2020 |
Open access
24
21
5
|
| 2020 |
Open access
18
15
1
|
| 2020 |
20
16
3
|
| 2020 |
Open access
27
26
9
|
| 2020 |
Open access
14
14
13
|
| 2020 |
Open access
46
44
8
|
| 2020 |
Open access
24
23
204
|
| 2020 |
41
39
14
|
| 2020 |
29
26
6
|
| 2019 |
Open access
36
33
7
|
| 2019 |
Open access
70
68
|
| 2019 |
128
118
3
|
| 2019 |
Open access
17
17
|
| 2019 |
17
17
120
|
| 2019 |
12
12
2
|
| 2019 |
Open access
92
84
4
|
| 2019 |
Open access
10
7
3
|
| 2019 |
40
35
|
| 2019 |
Open access
12
11
|
| 2019 |
27
24
|
| 2019 |
Open access
51
43
19
|
| 2019 |
Open access
7
6
3
|
| 2018 |
14
15
15
|
| 2018 |
18
14
4
|
| 2018 |
Open access
505
478
305
|
| 2018 |
7
4
1
|
| 2018 |
22
20
7
|
| 2018 |
23
21
|
| 2018 |
29
28
2
|
| 2018 |
Open access
20
16
2
|
| 2018 |
Open access
16
15
1
|
| 2018 |
Open access
10
12
5
|
| 2018 |
43
41
4
|
| 2018 |
Open access
18
16
1
|
| 2018 |
16
9
12
|
| 2018 |
16
13
4
|
| 2017 |
Open access
12
12
|
| 2017 |
Open access
31
31
12
|
| 2017 |
27
25
|
| 2017 |
Open access
28
27
|
| 2017 |
15
14
1
|
| 2017 |
Open access
10
9
|
| 2017 |
22
20
5
|
| 2017 |
1
|
| 2017 |
88
81
|
| 2017 |
48
44
4
|
| 2017 |
Open access
69
65
507
|
| 2017 |
Open access
51
43
18
|
| 2017 |
21
19
|
| 2016 |
21
20
4
|
| 2016 |
44
43
|
| 2016 |
60
56
22
|
| 2016 |
Open access
15
13
|
| 2016 |
Open access
37
36
|
| 2016 |
Open access
58
51
3
|
| 2016 |
46
36
4
|
| 2016 |
31
31
|
| 2016 |
2
|
| 2016 |
34
34
|
| 2016 |
31
29
|
| 2016 |
28
27
1
|
| 2016 |
35
36
|
| 2016 |
3
|
| 2016 |
10
8
|
| 2016 |
Open access
94
81
1
|
| 2016 |
Open access
20
16
34
|
| 2016 |
45
41
2
|
| 2016 |
Open access
45
44
2
|
| 2016 |
8
8
|
| 2015 |
Open access
12
12
3
|
| 2015 |
13
14
|
| 2015 |
Open access
239
210
252
|
| 2015 |
Open access
76
73
14
|
| 2015 |
Open access
32
30
1
|
| 2015 |
23
23
|
| 2015 |
30
28
4
|
| 2015 |
31
26
1
|
| 2015 |
Open access
15
12
3
|
| 2015 |
31
29
|
| 2015 |
28
26
|
| 2014 |
36
32
|
| 2014 |
Open access
43
38
|
| 2014 |
Open access
50
50
|
| 2014 |
85
79
|
| 2014 |
Open access
43
38
|
| 2014 |
33
26
|
| 2014 |
Open access
21
27
|
| 2014 |
Open access
40
34
|
| 2014 |
Open access
14
13
|
| 2014 |
17
15
|
| 2014 |
25
22
|
| 2013 |
177
172
|
| 2013 |
31
18
|
| 2013 |
32
33
|
| 2013 |
9
10
|
| 2013 |
Open access
9
6
|
| 2013 |
47
44
|
| 2013 |
37
34
|
| 2013 |
Open access
6
4
|
| 2013 |
Open access
5
|
| 2013 |
66
68
|
| 2013 |
146
133
|
| 2013 |
Open access
|
| 2012 |
83
76
|
| 2012 |
34
31
|
| 2012 |
30
28
|
| 2012 |
95
83
|
| 2012 |
46
43
|
| 2012 |
Open access
17
16
|
| 2012 |
48
42
|
| 2012 |
Open access
24
24
|
| 2011 |
48
48
|
| 2011 |
41
38
|
| 2011 |
55
47
|
| 2011 |
29
26
|
| 2011 |
34
32
|
| 2011 |
31
30
|
| 2011 |
55
49
|
| 2011 |
37
|
| 2011 |
47
48
|
| 2010 |
41
37
|
| 2010 |
136
120
|
| 2010 |
32
32
|
| 2010 |
17
15
|
| 2010 |
47
46
|
| 2010 |
131
115
|
| 2010 |
Open access
28
23
|
| 2010 |
86
64
|
| 2010 |
23
19
|
| 2010 |
85
78
|
| 2009 |
33
28
|
| 2009 |
86
73
|
| 2009 |
77
67
|
| 2009 |
32
28
|
| 2009 |
19
|
| 2009 |
104
93
|
| 2009 |
164
149
|
| 2008 |
5
6
|
| 2008 |
5
5
|
| 2008 |
46
44
|
| 2008 |
42
39
|
| 2008 |
55
52
|
| 2008 |
34
29
|
| 2008 |
37
36
|
| 2008 |
Open access
7
7
|
| 2008 |
21
18
|
| 2008 |
30
27
|
Research
The Prestidge research group is focused on Nanomedicine and BioPharmaceutical Engineering. Its Primary Mission is to: (1) Engineer novel particle based biomaterials with specific biological activity and their application to solve biopharmaceutical challenges. (2) Determine mechanisms for bioactivity through advanced biophysical analysis (3) Develop drug delivery solutions to address unmet clinical needs. Some of our Grand Challenges are to: (1) Deliver Challenging Therapeutic Molecules – For Better Medicines (2) Eradicate Bacterial Biofilms (3) Optimise Biotech and Pharmaceutical Processing and Manufacture
Research
| Details | Registry | Status |
|---|---|---|
|
Dried formulations of nanoparticle-coated capsules Prestidge, Clive Allan; Simovic, Spomenka |
AU | Granted |
|
Dried formulations of nanoparticle-coated capsules Prestidge, Clive Allan; Simovic, Spomenka |
JP | Granted |
|
Dried formulations of nanoparticle-coated capsules Prestidge, Clive Allan; Simovic, Spomenka |
US | Granted |
|
Drug delivery composition comprising polymer-lipid hybrid microparticles Prestidge, Clive Allan; Joyce, Paul Matthew |
Australia | Filed |
|
Drug release from nanoparticle-coated capsules Prestidge, Clive Allan; Simovic, Spomenk; Ghouchi Eskandar, Nasrin |
AU | Granted |
|
Drug release from nanoparticle-coated capsules Prestidge, Clive; Simovic, Spomenk; Ghouchi, Eskandar Nasrin |
EP | Filed |
|
Drug release from nanoparticle-coated capsules Prestidge, Clive; Simovic, Spomenk; Ghouchi, Eskandar Nasrin |
US | Granted |
|
Drug release from nanoparticle-coated capsules Prestidge, Clive; Simovic, Spomenk; Ghouchi Eskandar, Nasrin |
WO | Filed |
|
Nanoparticle-stabilized capsule formulation for treatment of inflammation Prestidge, Clive; Simovic, Spomenk |
US | Granted |
External engagement & recognition
| Organisation | Country |
|---|---|
| Academia Sinica | TAIWAN |
| Adelaide Pathology Partners | AUSTRALIA |
| ARC Centre of Excellence in Convergent Bio-Nano Science and Technology | AUSTRALIA |
| AstraZeneca (United Kingdom) | UNITED KINGDOM |
| Australian Centre for Applied Aquaculture Research | AUSTRALIA |
| Australian Nuclear Science and Technology Organisation | AUSTRALIA |
| Australian Research Council (ARC) | AUSTRALIA |
| Australian Synchrotron | AUSTRALIA |
| Behala College | INDIA |
| Central Adelaide Local Health Network Incorporated | AUSTRALIA |
| Ceramisphere | AUSTRALIA |
| CeramiSphere Pty Ltd | AUSTRALIA |
| Chalmers University of Technology | SWEDEN |
| Children's Cancer Institute Australia | AUSTRALIA |
| Clinpath Laboratories | AUSTRALIA |
| Complutense University of Madrid | SPAIN |
| CSIRO Australia (Commonwealth Scientific Industrial Research organisation) | AUSTRALIA |
| Daping Hospital | CHINA |
| Department of Surgery | UNITED STATES |
| Eurofins Panlabs | BELGIUM |
| Fermiscan Holdings Ltd. | AUSTRALIA |
| First Affiliated Hospital of Zhengzhou University | CHINA |
| Flinders University | AUSTRALIA |
| Georgia Institute of Technology | UNITED STATES |
| Ghent University | BELGIUM |
| Glantreo Limited | IRELAND |
| Gyan Ganga Institute of Technology and Sciences | INDIA |
| Hanson Institute | AUSTRALIA |
| Harbin Institute of Technology | CHINA |
| Harvard University | UNITED STATES |
| Helmholtz Institute for Pharmaceutical Research Saarland | GERMANY |
| Hong Kong Institute of Education | HONG KONG |
| Hudson Institute of Medical Research | AUSTRALIA |
| Imperial College of Science, Technology and Medicine | UNITED KINGDOM |
| Institut Charles Gerhardt Montpellier | FRANCE |
| Jadavpur University | INDIA |
| Johnson & Johnson | UNITED STATES |
| Macquarie University | AUSTRALIA |
| Massey University | NEW ZEALAND |
| Max Planck Institute for Molecular Genetics | GERMANY |
| McGill University | CANADA |
| Memorial Sloan Kettering Cancer Centre | UNITED STATES |
| Micromyx | UNITED STATES |
| Monash University | AUSTRALIA |
| Murdoch University | AUSTRALIA |
| Naresuan University | THAILAND |
| New England Biolabs (United States) | UNITED STATES |
| Ohio State University | UNITED STATES |
| Oulu University | FINLAND |
| Oulun Yliopisto | FINLAND |
| Pfizer (United States) | UNITED STATES |
| pSiMedica Ltd | UNITED KINGDOM |
| pSivida Limited | AUSTRALIA |
| RDC Clinical Pty Ltd | AUSTRALIA |
| RMIT University | AUSTRALIA |
| Royal Adelaide Hospital | AUSTRALIA |
| Rush University | UNITED STATES |
| Saarland University | GERMANY |
| South Australian Health and Medical and Research Institute (SAHMRI) | AUSTRALIA |
| Starpharma | AUSTRALIA |
| Stellenbosch University | SOUTH AFRICA |
| Sung Kyun Kwan University | KOREA, REPUBLIC OF (SOUTH) |
| Swiss Federal Institute of Technology Zurich (ETH) | SWITZERLAND |
| The Hospital for Sick Children | CANADA |
| The Queen Elizabeth Hospital | AUSTRALIA |
| The University of Wollongong | AUSTRALIA |
| Tianjin Hospital | CHINA |
| Umeå University | SWEDEN |
| University College Dublin | IRELAND |
| University of Adelaide | AUSTRALIA |
| University of Bristol | UNITED KINGDOM |
| University of California | UNITED STATES |
| University of California, Los Angeles | UNITED STATES |
| University of Copenhagen | DENMARK |
| University of Ferrara | ITALY |
| University of Groningen | NETHERLANDS |
| University of Hamburg | GERMANY |
| University of Ljubljana | SLOVENIA |
| University of Manitoba | CANADA |
| University of Melbourne | AUSTRALIA |
| University of New South Wales | AUSTRALIA |
| University of North Bengal | INDIA |
| University of Nottingham | UNITED KINGDOM |
| University of Otago | NEW ZEALAND |
| University of Parma | ITALY |
| University of Queensland | AUSTRALIA |
| University of Santiago de Compostela | SPAIN |
| University of South Australia | AUSTRALIA |
| University of Sydney | AUSTRALIA |
| University of Technology Sydney | AUSTRALIA |
| University of the Western Cape | SOUTH AFRICA |
| University of Tokyo | JAPAN |
| University of Toronto | CANADA |
| University of Valencia | SPAIN |
| University of Warwick | UNITED KINGDOM |
| University of Western Australia | AUSTRALIA |
| University of Wisconsin-Madison | UNITED STATES |
| Uppsala Biomedicinska Centrum | SWEDEN |
| Uppsala University | SWEDEN |
| Victoria University | AUSTRALIA |
| Women's and Children's Hospital | AUSTRALIA |
External engagement & recognition
| Engagement/recognition | Year |
|---|---|
MemberAmerican Association of Pharmaceutical Science (AAPS) |
2017 |
MemberRoyal Australian Chemical Institute (RACI) |
2017 |
MemberControlled Release Society |
2017 |
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| 110496 - Lipid-based Nanocarrier Enabled Delivery for Improved T-cell Immunotherapy | Current |
| 110502 - Developing advanced oral delivery formulations for treating leukemia | Current |
| 111602 - Improving mental health therapies by targeting the gut microbiome | Current |
| 460- Gut-Targeted Nanomedicines for Overcoming the Metabolic Side Effects of Antipsychotics | Current |
| A SN38 antibody prodrug conjugate strategy for cancer therapy | Current |
| Conquering antimicrobial resistant Gram-negative bacteria to address unmet clinical needs | Current |
| Design of Lipid Nanoparticles (LNPs) for mRNA-Based Cancer Vaccines | Current |
| Developing advanced oral delivery systems for antiviral drugs | Current |
| Development of a safe biomaterial-based therapy for obesity | Current |
| Engineering multifunctional hybrid materials for effective modulation of the gut microbiome | Current |
| Exploring the impact of formulation design on PUFA pharmacokinetics and biodistribution | Current |
| Formulation Design and Development of Oral Chemotherapeutic Prodrugs: In Vitro, In Vivo, and In Silico Characterisation and Evaluation | Current |
| Improving the efficacy of lung cancer therapies through targeted nanomedicine | Current |
| Lipid nanoparticles for delivery of nucleic acid vaccines | Current |
| Lipid-based formulations to overcome challenges in oral drugdelivery | Current |
| Understanding the Biological Performance of Plant Derived Fats and Proteins - Towards Improved Meat Analogues | Current |
| A combined lipophilic prodrug and lipid-based drug delivery approach to enable oral chemotherapy (with SN38) | Completed |
| Beyond the gastrointestinal cell layer: replication of the complex oral absorption barrier through enhanced in vitro models for nanoparticulate oral protein delivery | Completed |
| Biomimetic lipid prodrugs: balancing gastrointestinal toxicities and efficacy in oral chemotherapy | Completed |
| Cationic polymer mediated siRNA complexes: relationship between intracellular delivery and physicochemical properties | Completed |
| Combining porous nanostructure and lipid carriers to improve oral delivery systems for poorly water soluble drugs | Completed |
| Dendrimers interactions with lipid bilayers: mechanistic and kinetic studies | Completed |
| Designing nanostructured biomaterials with specific activities towards digestive enzymes for controlled lipid hydrolysis | Completed |
| Development of imaging methods/models to study oral vaccination and/or delivery of biologics | Completed |
| Improving nitric oxide delivery to staphylococcus aureus biofilms | Completed |
| Lipid liquid crystal nanostructures to enhance the delivery and efficacy of antimicrobials against bacterial biofilms | Completed |
| Lipid liquid crystalline nanoparticles: a delivery system for antimicrobial photodynamic therapy | Completed |
| Lipoceramic microparticles for enhancing oral anticancer drug delivery | Completed |
| Liposome-micelle hybrid systems for oral delivery of poorly water-soluble cardiovascular drug lovastatin and anticancer drugs paclitaxel and 5-fluorouracil | Completed |
| Microfluidic intestine-on-a-chip in vitro models for improved mechanistic understanding of intestinal drug and particulate carrier uptake | Completed |
| Microfluidic intestine-on-a-chip in vitro models for improved understanding of intestinal particulate carrier absorption and interaction with mucus | Completed |
| Molecular mechanisms of M cell signalling in the small intestine | Completed |
| Multi-compartmental emulsion systems for the oral delivery of subunit vaccines | Completed |
| Nanoparticle coated liposomes for encapsulation and delivery of proteins | Completed |
| Nanostructured clay materials for solidifying lipid-based drug delivery systems | Completed |
| Novel glyceryl monooleate (GMO) cubosomes stabilized using silica nanoparticles for the oral delivery of poorly water soluble drugs | Completed |
| Optimising the interfacial properties of porous silicon for effective control of molecular and biomolecular interactions | Completed |
| Optimizing silica encapsulated lipid-based oral drug delivery systems | Completed |
| Overcoming biological barriers in treating intracellular infections using lipid-based nanoparticles | Completed |
| Physicochemical and biopharmaceutical investigations of novel drug delivery systems for oral administration of poorly water-soluble drugs: Silica-lipid hybrid microcapsules | Completed |
| Polymeric micelles to improve the delivery of poorly soluble antimicrobial agents to bacterial and fungal biofilms | Completed |
| Polymer-lipid hybrid microparticles enhance the intracellular uptake and activity of rifampicin against bacterially infected macrophages | Completed |
| Porous silicon as a delivery system for poorly soluble drugs | Completed |
| Solid nanostructured formulations for the oral delivery of poorly water-soluble drugs: from bench to bedside | Completed |
| Supersaturated silica-lipid hybrids - overcoming the challenges of oral drug delivery | Completed |
| The impact of formulating 5-Fluorouracil into liposomes on its site-specific delivery to tumour tissue | Completed |
| The role of brain derived neurotrophic factor and the neurotrophin receptor p75NTR in the pathogenesis of Alzheimer¿s disease | Completed |
